PMID- 16925993
OWN - NLM
STAT- MEDLINE
DCOM- 20070111
LR  - 20221207
IS  - 0014-2999 (Print)
IS  - 0014-2999 (Linking)
VI  - 546
IP  - 1-3
DP  - 2006 Sep 28
TI  - Repeated administration of the substituted amphetamine p-methoxyamphetamine 
      produces reductions in cortical 5-HT transporter binding but not 5-HT content, 
      unlike 3,4-methylenedioxyamethamphetamine.
PG  - 74-81
AB  - Worldwide growth in p-methoxyamphetamine (PMA) usage amongst 'ecstasy' users 
      indicates a proportionally greater incidence of acute toxicity compared to 
      3,4-methylenedioxymethamphetamine (MDMA). While longer-term use of MDMA appears 
      to produce degeneration of 5-hydroxytryptamine (5-HT, serotonin) neurons, PMA 
      effects are poorly understood. The aim of this study was to determine the effect 
      of repeated PMA administration on two indices of 5-HT axonal degeneration, 
      cortical brain 5-HT transporter (SERT) density and 5-HT/5-hydroxyindolacetic acid 
      (5-HIAA) content. Treatment of male rats once daily for 4 days (10 or 20 mg/kg) 
      with PMA or MDMA resulted in significant reductions (20 mg/kg: 53% and 23% of 
      vehicle treatment respectively) in [(3)H]-paroxetine binding (SERT density) one 
      week after final drug administration. When rats were housed at a higher ambient 
      temperature (28 degrees C vs. 22 degrees C) for 6 h after dosing, no additive 
      effect was seen for either drug. A more intensive dosing regimen (10 or 20 mg/kg 
      twice daily for 4 days) was used to examine PMA/MDMA effects on cortical 5-HT 
      content. Two weeks after MDMA treatment, significant reductions in cortical 5-HT 
      content (20 mg/kg: 39% of vehicle treatment) were seen. However, PMA did not 
      alter cortical 5-HT content, yet reduced cortical 5-HIAA content (20 mg/kg: 72% 
      of vehicle treatment). These data suggest PMA has severe long-term implications 
      clinically for alteration of 5-HT neurotransmission that may differ from MDMA, 
      but may not necessarily be interpreted as a degeneration of 5-HT fibres.
FAU - Callaghan, Paul D
AU  - Callaghan PD
AD  - Discipline of Pharmacology, School of Medical Sciences, Medical School North, The 
      University of Adelaide, Adelaide, South Australia, 5005, Australia.
FAU - Farrand, Kirsten
AU  - Farrand K
FAU - Salem, Abdallah
AU  - Salem A
FAU - Hughes, Patrick
AU  - Hughes P
FAU - Daws, Lynette C
AU  - Daws LC
FAU - Irvine, Rodney J
AU  - Irvine RJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20060725
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Amphetamines)
RN  - 0 (Hallucinogens)
RN  - 0 (Serotonin Plasma Membrane Transport Proteins)
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - 102-32-9 (3,4-Dihydroxyphenylacetic Acid)
RN  - 333DO1RDJY (Serotonin)
RN  - 41VRH5220H (Paroxetine)
RN  - 54-16-0 (Hydroxyindoleacetic Acid)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - OVB8F8P39Q (4-methoxyamphetamine)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - 3,4-Dihydroxyphenylacetic Acid/metabolism
MH  - Amphetamines/metabolism/*pharmacology
MH  - Animals
MH  - Binding, Competitive
MH  - Brain Chemistry/drug effects
MH  - Cerebral Cortex/*drug effects/metabolism
MH  - Chromatography, High Pressure Liquid
MH  - Dopamine/*metabolism
MH  - Dose-Response Relationship, Drug
MH  - Electrochemistry
MH  - Hallucinogens/metabolism/*pharmacology
MH  - Hydroxyindoleacetic Acid/metabolism
MH  - Male
MH  - N-Methyl-3,4-methylenedioxyamphetamine/metabolism/*pharmacology
MH  - Paroxetine/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Serotonin/metabolism
MH  - Serotonin Plasma Membrane Transport Proteins/*drug effects/metabolism
MH  - Selective Serotonin Reuptake Inhibitors/metabolism
MH  - Synaptic Transmission/drug effects
MH  - Time Factors
EDAT- 2006/08/24 09:00
MHDA- 2007/01/12 09:00
CRDT- 2006/08/24 09:00
PHST- 2006/05/30 00:00 [received]
PHST- 2006/07/13 00:00 [revised]
PHST- 2006/07/17 00:00 [accepted]
PHST- 2006/08/24 09:00 [pubmed]
PHST- 2007/01/12 09:00 [medline]
PHST- 2006/08/24 09:00 [entrez]
AID - S0014-2999(06)00773-4 [pii]
AID - 10.1016/j.ejphar.2006.07.011 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2006 Sep 28;546(1-3):74-81. doi: 10.1016/j.ejphar.2006.07.011. 
      Epub 2006 Jul 25.